Clinical trial
Efficacy and Safety of Empagliflozin vs. Insulin Glargine add-on Therapy in Patients With Inadequately Controlled Type 2 Diabetes Under Triple Combination Therapy
NCT03473262 is registered in ClinicalTrials.gov with Chungbuk National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Empagliflozin vs. Insulin Glargine add-on Therapy in Patients With Inadequately Controlled Type 2 Diabetes Under Triple Combination Therapy
- Lead sponsor
- Chungbuk National University Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 1, 2017
- Completion date
- July 18, 2018
- Enrollment
- 200 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.